Journal Article > LetterFull Text
Lancet Global Health. 1 January 2025; Volume 13 (Issue 1); e24.; DOI: 10.1016/S2214-109X(24)00462-5
Lee JSF, Sued O, Ribeiro I, Jarvis JN, Burry J
Lancet Global Health. 1 January 2025; Volume 13 (Issue 1); e24.; DOI: 10.1016/S2214-109X(24)00462-5
Journal Article > LetterAbstract Only
Lancet HIV. 1 October 2024; Volume 11 (Issue 10); e711-e716.; DOI:10.1016/S2352-3018(24)00173-5
Venter WDF, Gandhi M, Sokhela S, Sikwese K, Bygrave H, et al.
Lancet HIV. 1 October 2024; Volume 11 (Issue 10); e711-e716.; DOI:10.1016/S2352-3018(24)00173-5
Journal Article > ReviewFull Text
Lancet Global Health. 1 September 2024; Volume 12 (Issue 9); e1552-e1559.; DOI:10.1016/S2214-109X(24)00225-0
Lee JSF, Cohen RM, Khan RA, Burry J, Casas EC, et al.
Lancet Global Health. 1 September 2024; Volume 12 (Issue 9); e1552-e1559.; DOI:10.1016/S2214-109X(24)00225-0
Journal Article > CommentaryAbstract Only
Clin Infect Dis. 29 August 2022; Volume 76 (Issue 3); e773-e775.; DOI:10.1093/cid/ciac689
Burry J, Casas CP, Ford NP
Clin Infect Dis. 29 August 2022; Volume 76 (Issue 3); e773-e775.; DOI:10.1093/cid/ciac689
Cryptococcal meningitis accounts for 1 in 5 AIDS-related deaths globally. World Health Organization guidelines strongly recommend a single high dose of liposomal amphotericin B as part of preferred treatment, but this drug remains unaffordable in most low- and middle-income countries. A proactive approach is needed from manufacturers and other stakeholders to improve access.
Journal Article > ReviewFull Text
Lancet Gastroenterol Hepatol. 1 February 2019; Volume 4 (Issue 2); 135-184.; DOI:10.1016/S2468-1253(18)30270-X
Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry J, et al.
Lancet Gastroenterol Hepatol. 1 February 2019; Volume 4 (Issue 2); 135-184.; DOI:10.1016/S2468-1253(18)30270-X
Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV and tuberculosis. Highly effective prevention measures and treatments have made the global elimination of viral hepatitis a realistic goal, endorsed by all WHO member states. Ambitious targets call for a global reduction in hepatitis-related mortality of 65% and a 90% reduction in new infections by 2030. This Commission draws together a wide range of expertise to appraise the current global situation and to identify priorities globally, regionally, and nationally needed to accelerate progress. We identify 20 heavily burdened countries that account for over 75% of the global burden of viral hepatitis. Key recommendations include a greater focus on national progress towards elimination with support given, if necessary, through innovative financing measures to ensure elimination programmes are fully funded by 2020. In addition to further measures to improve access to vaccination and treatment, greater attention needs to be paid to access to affordable, high-quality diagnostics if testing is to reach the levels needed to achieve elimination goals. Simplified, decentralised models of care removing requirements for specialised prescribing will be required to reach those in need, together with sustained efforts to tackle stigma and discrimination. We identify key examples of the progress that has already been made in many countries throughout the world, demonstrating that sustained and coordinated efforts can be successful in achieving the WHO elimination goals.
Journal Article > CommentaryFull Text
Lancet Infect Dis. 18 October 2018; Volume 19 (Issue 4); DOI:10.1016/S1473-3099(18)30493-6
Loyse A, Burry J, Cohn J, Ford NP, Chiller T, et al.
Lancet Infect Dis. 18 October 2018; Volume 19 (Issue 4); DOI:10.1016/S1473-3099(18)30493-6
In 2018, WHO issued guidelines for the diagnosis, prevention, and management of HIV-related cryptococcal disease. Two strategies are recommended to reduce the high mortality associated with HIV-related cryptococcal meningitis in low-income and middle-income countries (LMICs): optimised combination therapies for confirmed meningitis cases and cryptococcal antigen screening programmes for ambulatory people living with HIV who access care. WHO's preferred therapy for the treatment of HIV-related cryptococcal meningitis in LMICs is 1 week of amphotericin B plus flucytosine, and the alternative therapy is 2 weeks of fluconazole plus flucytosine. In the ACTA trial, 1-week (short course) amphotericin B plus flucytosine resulted in a 10-week mortality of 24% (95% CI -16 to 32) and 2 weeks of fluconazole and flucytosine resulted in a 10-week mortality of 35% (95% CI -29 to 41). However, with widely used fluconazole monotherapy, mortality because of HIV-related cryptococcal meningitis is approximately 70% in many African LMIC settings. Therefore, the potential to transform the management of HIV-related cryptococcal meningitis in resource-limited settings is substantial. Sustainable access to essential medicines, including flucytosine and amphotericin B, in LMICs is paramount and the focus of this Personal View.
Journal Article > ReviewFull Text
Curr Opin HIV AIDS. 1 January 2019; Volume 14 (Issue 1); DOI:10.1097/COH.0000000000000514
Khwairakpam G, Burry J
Curr Opin HIV AIDS. 1 January 2019; Volume 14 (Issue 1); DOI:10.1097/COH.0000000000000514
With increasing availability of generic direct-acting antivirals (DAAs) and associated price reductions, various governments, multilateral institutions, and donors have started providing testing and treatment for hepatitis C virus (HCV) infection. More data on the quality of these generic medicines and on cost-effectiveness of their use are becoming widely available. This review seeks to describe some of the treatment programs for HCV that are evolving in Cambodia, India, Indonesia, Malaysia, Myanmar, and Thailand.
Journal Article > CommentaryFull Text
PLoS Negl Trop Dis. 29 June 2017; Volume 11 (Issue 6); e0005575.; DOI:10.1371/journal.pntd.0005575
Molloy SF, Chiller T, Greene GS, Burry J, Govender NP, et al.
PLoS Negl Trop Dis. 29 June 2017; Volume 11 (Issue 6); e0005575.; DOI:10.1371/journal.pntd.0005575